FI944217A0 - Substituoidut pipekoliinihappojohdannaiset HIV-proteaasin estäjinä - Google Patents

Substituoidut pipekoliinihappojohdannaiset HIV-proteaasin estäjinä

Info

Publication number
FI944217A0
FI944217A0 FI944217A FI944217A FI944217A0 FI 944217 A0 FI944217 A0 FI 944217A0 FI 944217 A FI944217 A FI 944217A FI 944217 A FI944217 A FI 944217A FI 944217 A0 FI944217 A0 FI 944217A0
Authority
FI
Finland
Prior art keywords
acid derivatives
protease inhibitors
hiv protease
pipecolic acid
substituted pipecolic
Prior art date
Application number
FI944217A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI944217A (fi
Inventor
Paul Cates Anderson
Francois Soucy
Christiane Yoakim
Pierre Lavallee
Pierre Louis Beaulieu
Original Assignee
Bio Mega Boehringer Ingelheim
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bio Mega Boehringer Ingelheim filed Critical Bio Mega Boehringer Ingelheim
Publication of FI944217A publication Critical patent/FI944217A/fi
Publication of FI944217A0 publication Critical patent/FI944217A0/fi

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
FI944217A 1992-03-13 1994-09-13 Substituoidut pipekoliinihappojohdannaiset HIV-proteaasin estäjinä FI944217A0 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85071692A 1992-03-13 1992-03-13
PCT/CA1993/000096 WO1993018003A1 (fr) 1992-03-13 1993-03-12 Derivets substitues de l'acide pinecolinique comme inhibiteurs de la protease du virus de l'immunodeficience humaine

Publications (2)

Publication Number Publication Date
FI944217A FI944217A (fi) 1994-09-13
FI944217A0 true FI944217A0 (fi) 1994-09-13

Family

ID=25308925

Family Applications (1)

Application Number Title Priority Date Filing Date
FI944217A FI944217A0 (fi) 1992-03-13 1994-09-13 Substituoidut pipekoliinihappojohdannaiset HIV-proteaasin estäjinä

Country Status (25)

Country Link
US (1) US5807870A (fr)
EP (1) EP0560268B1 (fr)
JP (1) JP3258422B2 (fr)
KR (1) KR950700253A (fr)
AP (1) AP393A (fr)
AT (1) ATE116640T1 (fr)
AU (1) AU670582B2 (fr)
CA (1) CA2131185C (fr)
CZ (1) CZ285589B6 (fr)
DE (1) DE69300043T2 (fr)
DK (1) DK0560268T3 (fr)
ES (1) ES2066623T3 (fr)
FI (1) FI944217A0 (fr)
GR (1) GR3015622T3 (fr)
HU (2) HUT70617A (fr)
IL (1) IL105035A (fr)
NO (1) NO302570B1 (fr)
NZ (1) NZ251267A (fr)
OA (1) OA10092A (fr)
PH (1) PH30734A (fr)
PL (1) PL176362B1 (fr)
RU (1) RU2140911C1 (fr)
SK (1) SK280161B6 (fr)
WO (1) WO1993018003A1 (fr)
ZA (1) ZA931776B (fr)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5679688A (en) 1992-03-11 1997-10-21 Narhex Limited Quinaldoyl-amine derivatives of oxo-and hydroxy-substituted hydrocarbons
US6071895A (en) 1992-03-11 2000-06-06 Narhex Limited Polar-substituted hydrocarbons
US5888992A (en) 1992-03-11 1999-03-30 Narhex Limited Polar substituted hydrocarbons
MXPA93002392A (es) 1992-03-11 2005-02-04 Narhex Ltd Derivados amino de hidrocarburos-oxo e hidroxi-substituidos.
US5559256A (en) * 1992-07-20 1996-09-24 E. R. Squibb & Sons, Inc. Aminediol protease inhibitors
ES2123065T3 (es) 1992-08-25 1999-01-01 Searle & Co Hidroxietilamino-sulfonamidas utiles como inhibidores de proteasas retroviricas.
US5484926A (en) * 1993-10-07 1996-01-16 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
US5846993A (en) * 1992-12-22 1998-12-08 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
EP0610745A3 (en) * 1993-02-09 1994-09-28 Miles Inc Novel aminomethylene derivatives as immunosuppressants.
IL110898A0 (en) * 1993-09-10 1994-11-28 Narhex Australia Pty Ltd Polar-substituted hydrocarbons
US5527829A (en) * 1994-05-23 1996-06-18 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
CA2137406C (fr) * 1994-12-06 2005-09-13 Pierre Louis Beaulieu Procede de synthese d'intermediaires essentiels a la preparation d'inhibiteurs de la protease de vih
US6037157A (en) 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
US5914332A (en) 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
US5883252A (en) * 1996-01-26 1999-03-16 Vertex Pharmaceuticals Incorporated Aspartyl protease inhibitors
US5962725A (en) 1996-09-05 1999-10-05 Agouron Pharmaceuticals, Inc. Intermediate compounds useful for making HIV protease inhibitors such as nelfinavir
US5705647A (en) * 1996-09-05 1998-01-06 Agouron Pharmaceuticals, Inc. Intermediates for making HIV-protease inhibitors
US5925759A (en) 1996-09-05 1999-07-20 Agouron Pharmaceuticals, Inc. Methods of making HIV-protease inhibitors and intermediates for making HIV-protease inhibitors
US6232333B1 (en) 1996-11-21 2001-05-15 Abbott Laboratories Pharmaceutical composition
US6001851A (en) * 1997-03-13 1999-12-14 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
US6084107A (en) * 1997-09-05 2000-07-04 Agouron Pharmaceuticals, Inc. Intermediates for making HIV-protease inhibitors
US6251906B1 (en) 1998-05-15 2001-06-26 Abbott Laboratories Retroviral protease inhibiting compounds
CA2395987C (fr) 2000-01-19 2009-12-22 Abbott Laboratories Formulations pharmaceutiques ameliorees
DE60124080T2 (de) * 2000-03-23 2007-03-01 Elan Pharmaceuticals, Inc., San Francisco Verbindungen und verfahren zur behandlung der alzheimerschen krankheit
US6992081B2 (en) 2000-03-23 2006-01-31 Elan Pharmaceuticals, Inc. Compounds to treat Alzheimer's disease
US6846813B2 (en) * 2000-06-30 2005-01-25 Pharmacia & Upjohn Company Compounds to treat alzheimer's disease
EP1666452A2 (fr) 2000-06-30 2006-06-07 Elan Pharmaceuticals, Inc. Composés pour le traitement de la maladie d'Alzheimer
EP1299352B1 (fr) 2000-06-30 2005-12-28 Elan Pharmaceuticals, Inc. Composes pour traiter la maladie d'alzheimer
US20030096864A1 (en) * 2000-06-30 2003-05-22 Fang Lawrence Y. Compounds to treat alzheimer's disease
PE20020276A1 (es) 2000-06-30 2002-04-06 Elan Pharm Inc COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER
WO2003002122A1 (fr) * 2001-06-27 2003-01-09 Elan Pharmaceuticals, Inc. Derives de beta-hydroxyamine utiles dans le traitement de la maladie d'alzheimer
US20070213407A1 (en) * 2001-06-29 2007-09-13 Elan Pharmaceuticals And Pharmacia & Upjohn Company Llc Compounds to treat Alzheimer's disease
JP4482883B2 (ja) 2003-05-22 2010-06-16 リードケミカル株式会社 抗ウイルス作用を有する化合物およびその配合剤
EP2301919A1 (fr) 2004-06-10 2011-03-30 Board of Trustees of Michigan State University Synthèse du caprolactam à partir de la lysine
ES2426345T3 (es) * 2005-07-20 2013-10-22 Eli Lilly And Company Compuesto unidos en posición 1-amino
CN101541746B (zh) * 2007-02-20 2013-01-02 密执安州立大学董事会 用于生产己内酰胺的催化脱氨基
CN101631568B (zh) 2007-03-12 2012-08-22 尼克塔治疗公司 低聚物-蛋白酶抑制剂偶联物
WO2009114151A1 (fr) 2008-03-12 2009-09-17 Nektar Therapeutics Conjugués oligomères-acides aminés et oligomères-atazanavir
CN102105450A (zh) * 2008-07-24 2011-06-22 Draths公司 制备环酰胺单体的方法和相关的衍生物和方法
EP2440249A2 (fr) 2009-06-12 2012-04-18 Nektar Therapeutics Conjugués covalents comprenant un inhibiteurs de protéase, un oligomère non-peptidique soluble dans l'eau et une partie lipophilique

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3789347D1 (de) * 1986-10-14 1994-04-21 Banyu Pharma Co Ltd 5-Substituierte Amino-4-hydroxy-pentansäure-Derivate und deren Verwendung.
CA1340588C (fr) * 1988-06-13 1999-06-08 Balraj Krishan Handa Derive d'aminoacides
GB8927915D0 (en) * 1989-12-11 1990-02-14 Hoffmann La Roche Novel alcohols
GB8927913D0 (en) * 1989-12-11 1990-02-14 Hoffmann La Roche Amino acid derivatives
MY110227A (en) * 1991-08-12 1998-03-31 Ciba Geigy Ag 1-acylpiperindine compounds.
ZA931777B (en) * 1992-03-13 1993-09-23 Bio Mega Boehringer Ingelheim Substituted pyrrolidine derivatives as HIV protease inhibitors.
IL110255A (en) * 1993-07-16 1998-12-06 Merck & Co Inc Creation and resolution of 2 tert-butylcarboxamidopiprazine
US5480887A (en) * 1994-02-02 1996-01-02 Eli Lilly And Company Protease inhibitors
GB2292146A (en) * 1994-08-11 1996-02-14 Merck & Co Inc HIV protease inhibitors useful for the treatment of AIDS

Also Published As

Publication number Publication date
NZ251267A (en) 1996-09-25
AU670582B2 (en) 1996-07-25
EP0560268A1 (fr) 1993-09-15
FI944217A (fi) 1994-09-13
GR3015622T3 (en) 1995-06-30
PL176362B1 (pl) 1999-05-31
SK109094A3 (en) 1995-05-10
SK280161B6 (sk) 1999-09-10
CA2131185A1 (fr) 1993-09-16
NO302570B1 (no) 1998-03-23
HU211854A9 (en) 1995-12-28
KR950700253A (ko) 1995-01-16
ES2066623T3 (es) 1995-03-01
PH30734A (en) 1997-10-17
IL105035A0 (en) 1993-07-08
JPH0673004A (ja) 1994-03-15
NO943383L (no) 1994-09-12
HU9402613D0 (en) 1994-11-28
DK0560268T3 (da) 1995-06-12
JP3258422B2 (ja) 2002-02-18
DE69300043T2 (de) 1995-05-24
RU94040841A (ru) 1996-07-20
IL105035A (en) 1997-07-13
AP393A (en) 1995-08-07
NO943383D0 (no) 1994-09-12
WO1993018003A1 (fr) 1993-09-16
US5807870A (en) 1998-09-15
ATE116640T1 (de) 1995-01-15
CA2131185C (fr) 1997-05-27
HUT70617A (en) 1995-10-30
CZ285589B6 (cs) 1999-09-15
AU3880893A (en) 1993-10-05
AP9300495A0 (en) 1993-04-30
DE69300043D1 (de) 1995-02-16
RU2140911C1 (ru) 1999-11-10
CZ223294A3 (en) 1995-11-15
ZA931776B (en) 1993-09-24
EP0560268B1 (fr) 1995-01-04
OA10092A (en) 1996-12-18

Similar Documents

Publication Publication Date Title
FI944217A0 (fi) Substituoidut pipekoliinihappojohdannaiset HIV-proteaasin estäjinä
ATE286025T1 (de) Hiv protease inhibitoren
NO932620D0 (no) Amindiol-proteaseinhibitorer
NZ239359A (en) Peptide-boronic acid derivatives as serine protease inhibitors
NO891489D0 (no) Fremgangsmaate for fremstilling av hiv protease inhibitorer
FI944804A0 (fi) Pyrimidinyyliasetamideja elastaasin estäjinä
DK0606248T3 (da) Heteroarylaminer som hidtil ukendte acetylcholinesteraseinhibitorer
NO922673L (no) Nye hiv proteaseinhibitorer
FI935644A (fi) Retrovirusten proteaasi-inhibiittoreita
FI941712A0 (fi) Heterosykliset iminobismetyleenibisfosfonihappojohdannaiset
DE69311355D1 (de) Persäure-verbindungen
FI940133A0 (fi) Uudet nikotiinihappojohdannaiset
NO950212L (no) Indolinyl-N-hydroksyurinstoff- og -N-hydroksamsyrederivater som lipoksygenase-inhibitorer
DE69418656D1 (de) 2-acyloxycephemderivate als elastaseinhibitoren
NO920023L (no) Hiv-proteaseinhibitorer
DK658489D0 (da) Proteaseinhibitorer

Legal Events

Date Code Title Description
GB Transfer or assigment of application

Owner name: BOEHRINGER INGELHEIM (CANADA) LTD.